Combined measurement of CSF α-synuclein, phosphorylated and total tau, Aβ42, and neurofilament light chains may provide a robust method for differential diagnosis among PD, atypical parkinsonian syndromes, AD, and other neurodegenerative conditions [105]. The gene discussed is MAPT; the disease is Alzheimer disease.